In contrast to either monothereapy, combined inhibition of BRAFV600E and EGFR, both in vivo and in vitro, resulted in efficient silencing of the MAPK pathway, reflected by reduced tumor growth in and extended survival of animal subjects bearing BRAFV600E glioma xenografts. Here, EGFR is linked to glioma.